DealStreetAsia: LongeVC Targets $250M for Fund II, Bets on Opportunities in Asia’s Longevity Tech Growth

According to a report by InsightAce Analytic, the global market for longevity and anti-senescence therapy was valued at over $27.1 billion in 2023, with an estimated compound annual growth rate (CAGR) of 6.8% expected between 2023 and 2031. Many companies have made significant progress in this field, and more are expected to emerge in the coming years. At LongeVC, we are looking for companies working on completely breakthrough companies. And the people behind the technology are even more important to us.

In a recent interview with DealStreetAsia, LongeVC funding partner Garri Zmudze discussed our plans for Fund II, including focusing on the so-called ‘sci-fi longevity tech’. He also shared his backstory of investing in Alex Zhavoronkov’s Insilico Medicine, launching LongeVC, and plans for LongeVC's sister fund, Ani VC, which will focus on animal longevity and pet health.

You can read the full interview here.